Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain
CompletedPhase 2NCT00838799
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.
Study details
- Official title
- A Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Sponsor
- Forest Laboratories
- Collaborators
- Gedeon Richter Ltd.
- Start date
- 2009-02
- Primary completion
- 2010-04
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 54
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female outpatients 18 to 75 years of age * A diagnosis of painful diabetic neuropathy * Controlled blood glucose * Willingness to wash out all analgesic medications used for DPNP * Female patients either postmenopausal, surgically sterile, or practicing a medically acceptable method of contraception * Female patients who are not pregnant Exclusion Criteria: * Acute infections or cardiac problems * Past use of pregabalin * History of severe psychiatric disorder * History of any amputation due to diabetes * History of seizure disorder * Active diabetic foot ulcers
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00838799